These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8355770)

  • 1. Clean drugs for Italy?
    Nature; 1993 Aug; 364(6439):658. PubMed ID: 8355770
    [No Abstract]   [Full Text] [Related]  

  • 2. Italian health sector in disarray following more scandals.
    Abbott A
    Nature; 1993 Aug; 364(6439):663. PubMed ID: 8355773
    [No Abstract]   [Full Text] [Related]  

  • 3. Maximizing exclusivity for drug products.
    French H
    Nat Rev Drug Discov; 2005 Sep; 4(9):709. PubMed ID: 16178117
    [No Abstract]   [Full Text] [Related]  

  • 4. NIH urged to cap profits made on publicly funded research.
    Macilwain C
    Nature; 2000 Jul; 406(6791):5. PubMed ID: 10894508
    [No Abstract]   [Full Text] [Related]  

  • 5. [Reference prices].
    Rey Abella ME
    Aten Primaria; 1999 Sep; 24(5):252-4. PubMed ID: 10590555
    [No Abstract]   [Full Text] [Related]  

  • 6. Revised drug policy.
    Shelat AJ
    J Indian Med Assoc; 1995 Mar; 93(3):117-8. PubMed ID: 8522818
    [No Abstract]   [Full Text] [Related]  

  • 7. Validation--how much can the world afford? Are we getting value for money?
    Anisfeld MH
    J Pharm Sci Technol; 1994; 48(1):45-8. PubMed ID: 8004419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bid to limit prices on drugs using 'public' discoveries.
    Wadman M
    Nature; 1998 May; 393(6683):297. PubMed ID: 9620788
    [No Abstract]   [Full Text] [Related]  

  • 9. WHO must defend patients' interests, not industry.
    Cawthorne P; Ford N; Limpananont J; Tienudom N; Purahong W
    Lancet; 2007 Mar; 369(9566):974-5. PubMed ID: 17382809
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug price deal spells windfall for researchers.
    Bosch X
    Nature; 2001 Nov; 414(6860):138. PubMed ID: 11700514
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug shortage crisis resolution.
    Duffy E
    J Pharm Pract; 2012 Dec; 25(6):619-20. PubMed ID: 23222856
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmaceuticals and medical devices: business practices.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2014 Dec; ():1-38. PubMed ID: 25771555
    [No Abstract]   [Full Text] [Related]  

  • 13. Bringing business risk into sharp focus.
    Gruber B; Walsh E
    Nat Biotechnol; 2012 Jan; 30(1):30-2. PubMed ID: 22231088
    [No Abstract]   [Full Text] [Related]  

  • 14. [Development costs, regulation and audit in the German SHI Drug Sector].
    Kamp F; Walter P; Bücheler R
    Gesundheitswesen; 2014 Jan; 76(1):7-18. PubMed ID: 24446140
    [No Abstract]   [Full Text] [Related]  

  • 15. Fake pharmaceuticals: how they and relevant legislation or lack thereof contribute to consistently high and increasing drug prices.
    Moken MC
    Am J Law Med; 2003; 29(4):525-42. PubMed ID: 15119247
    [No Abstract]   [Full Text] [Related]  

  • 16. [Is openness in the drug market possible?].
    Dölle W; Schwabe U
    Internist (Berl); 1986 Jan; 27(1):21-31. PubMed ID: 3514513
    [No Abstract]   [Full Text] [Related]  

  • 17. Health Canada wants more funds from pharma.
    Vogel L
    CMAJ; 2017 Jun; 189(24):E845-E846. PubMed ID: 28630367
    [No Abstract]   [Full Text] [Related]  

  • 18. Biotech patents-business as usual?
    Lawrence S
    Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
    [No Abstract]   [Full Text] [Related]  

  • 19. Interview with Dr Richard Barker, Director General of the Association of the British Pharmaceutical Industry.
    Barker R
    Future Med Chem; 2009 Jun; 1(3):421-6. PubMed ID: 21426122
    [No Abstract]   [Full Text] [Related]  

  • 20. Medicines pricing singled out.
    Buchanan E
    S Afr Med J; 2004 May; 94(5):334. PubMed ID: 15211941
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.